# PICO Table
([switch to Risk of Bias table](risk-of-bias.md))

Study        | PMID                                    |Patients/population/problem|Intervention|Comparison|Outcome|
------------ | --------------------------------------|---------------------------|------------|----------|-------|
| Lee (Ultracet ER Study Group)<br>2013 | [24183364](http://pubmed.gov/24183364) |Adults with chronic back pain| Up to tramadol 300 mg and acetaminophen 2600 mg per day for one month |Placebo|Pain (VAS)|
| Peloso<br>2004 | [15570651](http://pubmed.gov/15570651) |Adults with chronic back pain |  Up to tramadol 300 mg and acetaminophen 2600 mg per day for three months   | Placebo | Pain (VAS)|
| Ruoff  (Protocol CAPSS-112 Study Group)<br>2003| [12809961](http://pubmed.gov/12809961) |Adults with chronic back pain                          | Up to tramadol 300 mg and acetaminophen 2600 mg per day for three months | Placebo |Pain (VAS)|
| Schiphorst<br>2014 | [24526247](http://pubmed.gov/24526247) |Adults with chronic back pain| Tramadol 225 mg and acetaminophen 1,950 mg per day for two weeks  |Placebo|Pain (VAS)|
| Schnitzer<br>2000 | [10743823](http://pubmed.gov/10743823) |Adults with chronic back painwho completed an open-label, run-in phase<br>• 35% withdrew from the run-in, due to adverse event or lack of efficacy | Tramadol up to 400 mg/day for one month |Placebo|Pain (VAS)|
| Uberall<br>2012 | [22970658](http://pubmed.gov/22970658) |Adults with chronic back pain| Tramadol 200 mg/day for one month |Placebo|Pain (11 point NRS)|
| Vorsanger<br>2008 | [18557165](http://pubmed.gov/18557165) |Adults with chronic back pain who completed an open-label, run-in phase.<br>• 38% withdrew from the run-in, due to adverse event or lack of efficacy | Tramadol 300 mg/day for three months |Placebo|Pain (VAS)|
